Faculty, Staff and Student Publications
Publication Date
2-1-2026
Journal
Arteriosclerosis, Thrombosis, and Vascular Biology
DOI
10.1161/ATVBAHA.125.323743
PMID
41410053
PMCID
PMC12922767
PubMedCentral® Posted Date
2-21-2026
PubMedCentral® Full Text Version
Author MSS
Abstract
C1INH (C1-inhibitor) is a multifunctional SERPIN (serine protease inhibitor) that functions as a major negative regulator of the complement, coagulation, and kallikrein-kinin systems. C1INH products were originally developed for the treatment of hereditary angioedema associated with C1INH deficiency. A growing body of literature indicates that C1INH products may find utility in the management of several other disease states. In this review, we detail the key biological activities of C1INH and consider the pathophysiological role of C1INH targets in many conditions. The therapeutic potential of exogenous C1INH is highlighted in the settings of thromboembolism, ischemia-reperfusion injury, sepsis, transplantation, and coronavirus disease 2019.
Keywords
Humans, Complement C1 Inhibitor Protein, Animals, COVID-19, Vascular Diseases, Reperfusion Injury, Blood Coagulation, Sepsis, C1-inhibitor protein, Hereditary Angioedema, Blood Coagulation, Complement, Vascular Diseases
Published Open-Access
yes
Recommended Citation
Linda Sundler Björkman, Harish Eswaran, and Steven P Grover, "Therapeutic Potential of C1-Inhibitor in Vascular Diseases and Beyond" (2026). Faculty, Staff and Student Publications. 3560.
https://digitalcommons.library.tmc.edu/uthmed_docs/3560